BørsenDigital dynamo venter vækstboom i sundhed
Our mission is to develop digital health products that bring research, care, and technology together with the ultimate goal of helping people live longer and better lives.
Code to Save Lives
Dawn provides life-changing digital health therapies driving improved patient outcomes beyond the pill. We deliver strategic consulting and develop innovative digital health solutions in close collaboration with the pharmaceutical, medical device, and biotech industries.
We envision a connected healthcare industry that efficienctly develops individualized treatments for patients and empowers practitioners to choose and manage the right treatments.
As an ISO13485:2016 certified developer of regulated digital health products, Dawn delivers value throughout the entire project lifecycle from concept and launch, to ongoing maintenance, support, and user acquisition.
We are experienced in a wide variety of disease areas.
From the media? Get our press kit
MedWatchDigitalt sundhedsselskab skilles ud fra moderselskabet Trifork
ITWatchDigitalt sundhedsselskab indleder udskillelse af Trifork
Børsen33-årige Daniel Daugaard har ikke holdt fri i to år: “Vi ramte det perfekte tidspunkt at starte”
JPMathias Andersen arbejder dagligt på at redde menneskeliv med smartphonen
SynapseThinking beyond the needs of today
FinansDigital sundhedsvirksomhed: »Vi kan udvikle applikationer, der kan bryde smittekæden, men vi er låst på hænder og fødder«
Want to do meaningful work? Join us!
We are a passionate and dedicated mix of designers, engineers, regulatory and quality specialists and business consultants who want to make a difference in the lives of people living with diseases.
Working at Dawn Health is more than just a job. We are not just looking for new employees. We are looking for deeply passionate souls, gifted minds, innovators, team players, entrepreneurs and people who believe they can change the world. We love to build things, change the status quo and we drive a new digital health agenda that will impact 1 million patients by 2030.